PepGen Inc (PEPG)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.52-6.67%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge PepGen Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.298
Annual ending 2026-12-31
Revenue	—	37.46M
EPS	—	-1.083
Annual ending 2027-12-31
Revenue	—	4.61M
EPS	—	-1.106

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain strong cash runway into 2H 2027	A primary condition in PepGen Inc's published investment case. The stated target is Sufficient cash to fund operations through second half of 2027.	Intact	Cash falls short of funding operations through 2H 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Cash, cash equivalents and marketable securities declined from $132.3M in 2026-Q1 to $117.2M in 2026-Q2, yet management maintains the cash runway is sufficient to fund operations into 4Q 2027. The trajectory shows a modest cash burn but management is delivering on the stated cash runway guidance. Delivery assessment Oct 24, 2026
Report FREEDOM2 10 mg/kg clinical results in 2H 2026	They plan to report key clinical results in late 2026 and 2027.	Intact	Failure to report or negative results from FREEDOM2 10 mg/kg cohort in 2H 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Report FREEDOM2 12.5 mg/kg clinical results in 2027	They plan to report key clinical results in late 2026 and 2027.	Intact	Failure to report or negative results from FREEDOM2 12.5 mg/kg cohort in 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.11

$-1.23 → $-1.11 · observed estimates

FY2027 revenueUnavailable

$0.00B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.23	$0	7 / 7
2026-07-25	$-1.23	$0	7 / 7
2026-07-26	$-1.23	$0	7 / 7
2026-07-27	$-1.19	Unavailable	6 / 4
2026-07-28	$-1.19	Unavailable	6 / 4
2026-07-29	$-1.23	$0	7 / 7
2026-07-30	$-1.23	$0	7 / 7
2026-07-31	$-1.19	Unavailable	6 / 4
2026-08-01	$-1.19	Unavailable	6 / 4
2026-08-02	$-1.23	$0	7 / 7
2026-08-03	$-1.19	Unavailable	6 / 4
2026-08-04	$-1.19	Unavailable	6 / 4
2026-08-05	$-1.19	Unavailable	6 / 4
2026-08-06	$-1.19	Unavailable	6 / 4
2026-08-07	$-1.19	Unavailable	6 / 4
2026-08-08	$-1.05	$0	6 / 7
2026-08-09	$-1.04	$0	6 / 7
2026-08-10	$-1.04	$0	6 / 7
2026-08-12	$-1.04	$0	6 / 7
2026-08-13	$-1.19	Unavailable	6 / 4
2026-08-14	$-1.19	Unavailable	6 / 4
2026-08-15	$-1.19	Unavailable	6 / 4
2026-08-16	$-1.19	Unavailable	6 / 4
2026-08-17	$-1.19	Unavailable	6 / 4
2026-08-18	$-1.19	Unavailable	6 / 4
2026-08-19	$-1.19	Unavailable	6 / 4
2026-08-20	$-1.09	Unavailable	6 / 4
2026-08-21	$-1.09	Unavailable	6 / 4
2026-08-22	$-1.09	Unavailable	6 / 4
2026-08-23	$-1.09	Unavailable	6 / 4
2026-08-24	$-1.09	Unavailable	6 / 4
2026-08-25	$-1.09	Unavailable	6 / 4
2026-08-26	$-1.09	Unavailable	6 / 4
2026-08-27	$-1.09	Unavailable	6 / 4
2026-08-28	$-1.09	Unavailable	6 / 4
2026-08-29	$-1.09	Unavailable	6 / 4
2026-08-30	$-1.09	Unavailable	6 / 4
2026-08-31	$-1.09	Unavailable	6 / 4
2026-09-01	$-1.09	Unavailable	6 / 4
2026-09-02	$-1.09	Unavailable	6 / 4
2026-09-03	$-1.09	Unavailable	6 / 4
2026-09-04	$-1.09	Unavailable	6 / 4
2026-09-05	$-1.09	Unavailable	6 / 4
2026-09-06	$-1.09	Unavailable	6 / 4
2026-09-07	$-1.09	Unavailable	6 / 4
2026-09-08	$-1.09	Unavailable	6 / 4
2026-09-09	$-1.09	Unavailable	6 / 4
2026-09-10	$-1.09	Unavailable	6 / 4
2026-09-11	$-1.09	Unavailable	6 / 4
2026-09-12	$-1.09	Unavailable	6 / 4
2026-09-13	$-1.09	Unavailable	6 / 4
2026-09-14	$-1.09	Unavailable	6 / 4
2026-09-15	$-1.09	Unavailable	6 / 4
2026-09-16	$-1.09	Unavailable	6 / 4
2026-09-17	$-1.09	Unavailable	6 / 4
2026-09-18	$-1.09	Unavailable	6 / 4
2026-09-19	$-1.09	Unavailable	6 / 4
2026-09-20	$-1.09	Unavailable	6 / 4
2026-09-21	$-1.09	Unavailable	6 / 4
2026-09-22	$-1.09	Unavailable	6 / 4
2026-09-23	$-1.09	Unavailable	6 / 4
2026-09-24	$-1.09	Unavailable	6 / 4
2026-09-25	$-1.09	Unavailable	6 / 4
2026-09-26	$-1.09	Unavailable	6 / 4
2026-09-27	$-1.09	Unavailable	6 / 4
2026-09-28	$-1.09	Unavailable	6 / 4
2026-09-29	$-1.09	Unavailable	6 / 4
2026-09-30	$-1.09	Unavailable	6 / 4
2026-10-01	$-1.09	Unavailable	6 / 4
2026-10-02	$-1.09	Unavailable	6 / 4
2026-10-03	$-1.09	Unavailable	6 / 4
2026-10-04	$-1.09	Unavailable	6 / 4
2026-10-05	$-1.09	Unavailable	6 / 4
2026-10-06	$-1.09	Unavailable	6 / 4
2026-10-07	$-1.09	Unavailable	6 / 4
2026-10-08	$-1.11	Unavailable	6 / 3
2026-10-09	$-1.11	Unavailable	6 / 3
2026-10-10	$-1.11	Unavailable	6 / 3
2026-10-11	$-1.11	Unavailable	6 / 3
2026-10-12	$-1.11	Unavailable	6 / 3
2026-10-13	$-1.11	Unavailable	6 / 3
2026-10-14	$-1.11	Unavailable	6 / 3
2026-10-15	$-1.11	Unavailable	6 / 3
2026-10-16	$-1.11	Unavailable	6 / 3
2026-10-17	$-1.11	Unavailable	6 / 3
2026-10-18	$-1.11	Unavailable	6 / 3
2026-10-19	$-1.11	Unavailable	6 / 3
2026-10-20	$-1.11	Unavailable	6 / 3
2026-10-21	$-1.11	Unavailable	6 / 3
2026-10-22	$-1.11	Unavailable	6 / 3
2026-10-23	$-1.11	Unavailable	6 / 3
2026-10-24	$-1.11	Unavailable	6 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	6	1
2026-06-01	7	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain strong cash runway into 2H 2027Direct metric needs a verified mapping
Report FREEDOM2 10 mg/kg clinical results in 2H 2026Direct metric needs a verified mapping
Report FREEDOM2 12.5 mg/kg clinical results in 2027Direct metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.2%Typical daily move · historical

Downside history

-81.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

PepGen Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business rather than an established compounder, and the evidence snapshot rates earnings quality and value as loss-making. The thesis is in watch state, with low overall confidence and high risk.

What's priced into PepGen Inc

The snapshot provides no valuation multiple or direct measure of market expectations, so whether PEPG is cheap or expensive versus peers is unclear. Recent earnings beats and stronger Healthcare sector context may support expectations, but the evidence does not show how much of that is already reflected.

What the fundamentals likely do

Near term, the record of three recent earnings beats is positive, but financial performance remains below its industry cohort and the miss risk is elevated. Cash declined from $132.3 million in the first quarter of 2026 to $117.2 million in the second, while management says it can fund operations into the fourth quarter of 2027. Trial progress remains on stated timelines, with FREEDOM2 10 mg/kg results expected in November 2026 and 12.5 mg/kg results expected in the first half of 2027.

What PepGen Inc hinges on

The multi-year thesis depends on the FREEDOM2 results and whether the cash runway remains sufficient through those milestones. Near-term guidance cuts or further weakening in job growth could add pressure, while continued strength from Healthcare bellwethers could support sector momentum.